Thanks for emailing that article!
Alcon recently announced United States FDA approval for its new Simbrinza™ Suspension drug, indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma. Elevated IOP is the only treatable risk factor for glaucoma.
Glaucoma is a group of eye diseases that lead to progressive damage of the optic nerve and can result in gradual, irreversible loss of vision, and eventually blindness, if left untreated. Glaucoma affects more than 2.2 million Americans and is the second-leading cause of blindness worldwide.
Simbrinza™ is a fixed-dose combination medication that offers a wide range of treatment possibilities. It is currently the only available, fixed-dose combination therapy for glaucoma in the US without a beta blocker. The new ophthalmic suspension is a combination of a carbonic anhydrase inhibitor (Brinzolamide 1.0%) and an alpha 2 adrenergic receptor agonist (Brimonidine Tartrate 0.2%). It combines the two drugs into one multi-dose bottle, helping to reduce the medication burden for glaucoma patients.
“Simbrinza™ represents an important new option for treating glaucoma patients with elevated IOP,” said Gregory Katz, MD, Glaucoma Service, St. Joseph Mercy Medical Center, Ann Arbor, Michigan.
The FDA approval of Simbrinza™ is based on data from two pivotal Phase III clinical trials with approximately 1,300 patients. For more information, visit the Alcon website.
Last reviewed on October 29, 2017